{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:18:25Z","timestamp":1784157505004,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2021.01.014","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T02:08:44Z","timestamp":1612145324000},"page":"335-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry"],"prefix":"10.1016","volume":"24","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-2929","authenticated-orcid":false,"given":"Sergio","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-8534","authenticated-orcid":false,"given":"Marco","family":"Bergevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Keynan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.jgar.2021.01.014_bib0005","doi-asserted-by":"crossref","first-page":"iv5","DOI":"10.1093\/jac\/dkz283","article-title":"42936 pathogens from Canadian hospitals: 10 years of results (2007\u201316) from the CANWARD surveillance study","volume":"74","author":"Zhanel","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.014_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jgar.2021.01.014_bib0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with and without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.01.014_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"September","key":"10.1016\/j.jgar.2021.01.014_bib0025","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","author":"Overcash","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.jgar.2021.01.014_bib0030","doi-asserted-by":"crossref","first-page":"iv55","DOI":"10.1093\/jac\/dkz288","article-title":"Characterization of MRSA in Canada from 2007 to 2016","volume":"74","author":"Nichol","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.014_bib0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jac\/dkp176","article-title":"Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model","volume":"64","author":"Zhanel","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.014_bib0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/1440-1681.12195","article-title":"Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus","volume":"41","author":"Salem","year":"2014","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jgar.2021.01.014_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10096-013-1959-9","article-title":"Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model","volume":"33","author":"Barnea","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.014_bib0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1155\/2010\/296760","article-title":"Ceftobiprole: first reported experience in osteomyelitis","volume":"21","author":"MacDonald","year":"2010","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jgar.2021.01.014_bib0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.07.020","article-title":"Ceftobiprole for the treatment of infective endocarditis: a case series","volume":"20","author":"Tascini","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.01.014_bib0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jgar.2020.03.010","article-title":"Real-life experience with ceftobiprole in a tertiary-care hospital","volume":"22","author":"Durante-Mangoni","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.01.014_bib0065","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2147\/IDR.S254395","article-title":"Ceftobiprole for treatment of MRSA blood stream infection: a case series","volume":"13","author":"Mahmoud","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.01.014_bib0070","first-page":"24","article-title":"Ceftobiprole: experience in staphylococcal bacteremia","volume":"32","author":"Soriano","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2021.01.014_bib0075","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.014_bib0080","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.06057-11","article-title":"Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus","volume":"56","author":"Fernandez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.014_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fmb-2019-0332","article-title":"Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia; a novel protocol for a double-blind phase III trial","volume":"15","author":"Hamed","year":"2020","journal-title":"Future Microbiol"},{"issue":"September","key":"10.1016\/j.jgar.2021.01.014_bib0090","article-title":"Ceftobiprole and pneumonia in adults admitted to emergency department: is it time to assess the new therapeutic algorithm?","author":"Crapis","year":"2020","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2021.01.014_bib0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12879-019-3820-y","article-title":"Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials","volume":"19","author":"Scheeren","year":"2019","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652100028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652100028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:44Z","timestamp":1761991004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652100028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":19,"alternative-id":["S221371652100028X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}